2 months Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates Zacks
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of 8.75% and 2.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X